S erotonin (5-hydroxytryptamine [5-HT]) receptors regulate feelings of satiety and food intake. 1 The serotonergic antiobesity compounds fenfluramine and dexfenfluramine were effective in causing weight loss but were associated with valvular heart disease, especially aortic and mitral valve insufficiency. [2] [3] [4] [5] These compounds were nonselective, affecting serotonin transporters as well as multiple serotonin receptor subtypes. 6-8 Subsequent research and clinical observations implicated activation of the 5-HT 2B receptor subtype as the cause of serotonergic valvulopathy. 7, [9] [10] [11] The 5-HT 2B receptors are expressed on cardiac valvular interstitial cells and when stimulated produce a characteristic valvulopathy that is also observed with the nonselective dopamine agonists pergolide and cabergoline. 12
a preplanned integrated analysis. The results of this analysis, which examines whether 1-year treatment with lorcaserin impacts the risk of cardiac valvular regurgitation, are reported herein. In addition, the potential confounding influence of weight loss or decrease in BMI on echocardiographic findings of valvular regurgitation was explored. 18 
Methods

Design and Study Population
The studies were conducted at academic and private research sites in the United States. Institutional review boards reviewed and approved the protocols for each research site. All patients provided written informed consent before participation in the trials.
Integrated echocardiographic and body weight data from the 3 lorcaserin phase 3 clinical trials, which in total randomized 7794 patients, were analyzed. [13] [14] [15] Detailed methods for each of the studies have been published. [13] [14] [15] In brief, 10 mg lorcaserin twice daily (Arena Pharmaceuticals, Inc, San Diego, CA) or placebo was administered to overweight/obese subjects, some with diabetes mellitus, for ≤104 weeks. Echocardiograms were obtained at baseline, week 24, and week 52 in all 3 studies. Only data for the first year of treatment were included in this integrated echocardiographic analysis, because only 1 study included a second year. The prespecified primary echocardiographic end point was the proportion of patients with FDA-defined valvulopathy at week 52 (among those without it at baseline), defined as an echocardiographic finding of mild or greater aortic valve regurgitation (AR) and moderate or greater mitral valve regurgitation (MR).
Echocardiography
All sonographers and cardiologists received training through a central core facility (Biomedical Systems, St. Louis, MO) for standardized study procedures adherent to the American Society of Echocardiography guidelines and were required to submit a qualifying echocardiogram before patient enrollment commenced. 19, 20 Each echocardiogram was interpreted independently by 2 cardiologists. Aortic, mitral, and tricuspid regurgitation were evaluated using the recommended American Society of Echocardiography-integrated approach, 20 with the following modification. As the early fenfluramine signal was appreciated by evaluating lower grades of regurgitation, we felt that it was important to include nonclinically significant trace regurgitation. A final grade of absent, trace, mild, moderate, or severe was recorded, and pulmonic regurgitation was scored simply as absent or present. A difference in ejection fraction value of >10%, a difference in severity of AR or MR (other than absent versus trace), or a difference of >10 mm Hg in pulmonary pressure among the 2 cardiologists triggered adjudication by a third cardiologist.
For the first study, 14 an Echocardiographic Data Safety Monitoring Board was created to establish safety criteria and stopping rules and to monitor patient safety related to echocardiographic findings. This Echocardiographic Data Safety Monitoring Board included level 3 echocardiographers and an independent statistician. The Echocardiographic Data Safety Monitoring Board reviewed all 6-month and 12-month echocardiographic results and had access to all echocardiograms to evaluate the safety of continuing the study to the predefined treatment duration end points.
The first study excluded patients with FDA-defined valvulopathy, mitral or aortic valve stenosis of mild or greater severity, a left ventricular ejection fraction <45%, a pulmonary artery systolic pressure (PASP) >40 mm Hg, or a tricuspid regurgitation (TR) jet >2.9 m/s. No exclusion criteria based on echocardiographic data were used in the other 2 studies. Additional exclusion criteria are detailed in the individual study reports. [13] [14] [15] 
Statistical Analysis
The prespecified primary analysis included all randomized patients who had taken ≥1 dose of study drug and who had a baseline echocardiogram and ≥1 postbaseline echocardiogram; last-observation-carried-forward imputation was applied for missing values (randomized-echo population). Sensitivity analyses were performed as described in the online-only Data Supplement Material (onlineonly Data Supplement Statistical Considerations and Table I in the online-only Data Supplement) using the population of patients who completed the full 52 weeks of study participation (completers), for which no data imputation was required.
The primary end point was the proportion of patients with echocardiographic FDA-defined valvulopathy at week 52 not present at baseline/screening. Total enrollment for the 3 trials was powered to rule out ≥1.25% risk difference between the estimated 1-year rate of FDAdefined valvulopathy in the integrated lorcaserin group and the placebo group. The derivation of 1.25% for exclusion was from 50% of the 2.5% estimated placebo rate from an interim 12-month review of the first study by the Echocardiographic Data Safety Monitoring Board. 14 Secondary analyses of the primary end point included the risk ratio for FDA-defined valvulopathy. Increases and decreases in valvular regurgitation at individual aortic, mitral, and tricuspid valves were also evaluated.
Possible associations between body weight or BMI change and the presence of FDA-defined valvulopathy were analyzed using logistic regression methodology 21 as described in the online-only Data Supplement Statistical Considerations. Table 1 summarizes the demographics and baseline characteristics of the analysis populations. Subjects were well-matched across treatment groups; the majority comprised middle-aged white women with mean echocardiographic parameters within normal limits (Table 1) . 22 Among the entire population of obese subjects screened for the 3 studies, 5.1% met the criteria for FDA-defined valvulopathy. Among the population of patients enrolled in the studies, 2.7% randomized to lorcaserin and 2.4% randomized to placebo met echocardiographic criteria for FDA-defined valvulopathy. Of the patients with pre-existing FDA-defined valvulopathy, 80.8% of cases met valvulopathy criteria as a result of mild or greater AR; moderate MR or moderate MR plus mild or moderate AR made up the remainder.
Results
Demographics and Disposition
A summary of patient disposition is provided in Figure I of the online-only Data Supplement (Consort diagram). In total, 6897 patients (including those who took no study drug) were randomized to the placebo and lorcaserin twice-daily groups; 2696 patients assigned to lorcaserin and 2553 assigned to placebo provided week 52 echocardiographic data for the randomized-echo analyses. The completer echo population of patients who completed 52 weeks of follow-up with their randomly assigned treatment provided echocardiographic data for 1867 patients on lorcaserin and 1635 on placebo.
Echocardiographic FDA-Defined Valvulopathy
At week 52, 2.04% (95% CI, 1.56-2.66) of patients on placebo and 2.37% (95% CI, 1.86-3.02) of patients on lorcaserin had echocardiographic FDA-defined valvulopathy that was not present at baseline (randomized-echo analysis; Table 2 ).
The difference in absolute risk was 0.33%; the upper bounds of both the 2-sided 90% and 95% CIs were below the prespecified 1.25% (90% CI, −0.33 to 1.00; 95% CI, −0.46 to 1.13) for risk exclusion. The risk ratio for valvulopathy in the lorcaserin group at week 52 was 1.16× than that in the placebo group (95% CI, 0.81-1.67; Figure 1 ). The risk difference and risk ratio for FDA-defined valvulopathy in the lorcaserin group at week 24 were similar to those at week 52 ( Table 2) . For the completer population, the week 52 risk difference (0.08; 90% CI, −0.78 to 0.95; 95% CI, −0.95 to 1.12) and risk ratio (1.03; 95% CI, 0.68-1.57) were slightly lower than in the randomized-echo population (Table 2; Figure 1 ).
Progression or Regression of Echocardiographic FDA-Defined Valvulopathy
To evaluate the persistence and variability of echocardiographic FDA-defined valvulopathy, the subset of patients who completed 52 weeks of follow-up with their randomly assigned treatment and had an echocardiogram at all of the 3 time points were evaluated. At each time point, the proportion of patients from the previous time point meeting FDA-defined valvulopathy criteria was calculated ( Figure 2 ). At week 24, 2.1% of placebo and 2.4% of lorcaserin recipients had valvulopathy. Among these, 52.9% and 57.8%, respectively, no longer met the criteria for valvulopathy at week 52. Among Mean±SD, unless otherwise indicated. AR indicates aortic regurgitation; BMI, body mass index; FDA, Food and Drug Administration; and MR, mitral valve regurgitation. *Includes all randomized patients except for 9 patients who never took any dose of study drug ( Figure I in the online-only Data Supplement). †Includes all randomized patients who received ≥1 dose of study drug, had ≥1 postbaseline body weight recorded, had absence of FDA-defined valvulopathy by echocardiographic data at baseline, and had echocardiographic data at ≥1 postbaseline time points. ‡Includes all patients in the randomized echo population who completed 52 wk of follow-up with their randomly assigned treatment. §Denominator is total number of patients in corresponding analysis population. ║Denominator is number of patients with valvulopathy in corresponding analysis population. Sum of MR and AR percentages may be >100, because some patients met both MR and AR criteria for FDA-defined valvulopathy. the 2.1% (placebo) and 2.9% (lorcaserin) of patients with FDA-defined valvulopathy at baseline, 65.7% (placebo) and 67.9% (lorcaserin) still met the criteria for valvulopathy at week 24. At week 52, valvulopathy persisted for some and not others, such that 57.1% (placebo; 20 of 35) and 50% (lorcaserin; 28 of 56) of the baseline cases persisted for 1 year. In short, there was often movement of 1 grade of regurgitation in either direction in both treatment groups.
Analysis of Regurgitant Grade for Individual Cardiac Valves
Changes in the regurgitant grades for each individual valve were also evaluated; the majority in both treatment groups experienced no changes in regurgitant grade at any cardiac valve. Figure 3 shows a summary of specific changes from baseline to week 52 by grade. To avoid further complexity, the figure excludes 1 placebo patient who developed severe MR at week 52 (moderate at baseline) and 1 placebo patient who had severe TR at week 52 (moderate at baseline). No lorcaserin patient had severe regurgitation of any valve at week 52. The majority of shifts in AR was between absent and trace and, in MR and TR, was largely restricted to the absent, trace, and mild grades. Differences between lorcaserin and placebo were small for each valve. The total proportion of patients who experienced any increase in AR, MR, TR, or pulmonic regurgitation grade in the lorcaserin group had essentially no or minimal differences from the placebo group (Table II in 
Association of Change in Weight or BMI With Presence of Echocardiographic FDA-Defined Valvulopathy
The prevalence of mitral and tricuspid valvular regurgitation was previously shown to be inversely related to BMI. 18 In the present studies, patients on lorcaserin and placebo experienced mean (±SEM) decreases in weight of −5.6±0.12% and −2.3±0.12% (P<0.001) and BMI changes of −2.0±0.04 and
Table 2. Analysis of Proportion of Patients Who Developed FDA-Defined Valvulopathy From Baseline to Week 24 and Week 52
Week 24
Week 52 Patients with baseline FDA-defined valvulopathy were excluded. AR indicates aortic regurgitation; CI, confidence interval; FDA, Food and Drug Administration; MR, mitral regurgitation; and RR, risk ratio.
*Last-observation-carried-forward imputation used for missing values. Includes all randomized patients who received ≥1 dose of study drug, had ≥1 postbaseline body weight recorded, had absence of FDA-defined valvulopathy by echocardiographic data at baseline, and had echocardiographic data at ≥1 postbaseline time point(s).
†Denominator is total number of patients in corresponding analysis population. ‡Computed using Cochran-Mantel-Haenszel weighted normal approximation method with stratification by protocol. Criterion for exclusion by risk difference confidence interval ≤1. 25 .
§Denominator is number of patients with valvulopathy in corresponding analysis population. Sum of MR and AR percentages may be >100, because some patients met both MR and AR criteria for FDA-defined valvulopathy. −0.8±0.05 kg/m 2 (P<0.001), respectively, from baseline to week 52 by intent-to-treat analysis using last-observation-carriedforward imputation for missing values. Exploratory statistical analyses were performed to evaluate whether changes in these variables during the lorcaserin trials were associated with the presence of FDA-defined valvulopathy. To avoid potentially confounding, nonweight-related effects of lorcaserin, the initial analyses used only the placebo group. A stepwise series of analyses showed a similar association between weight and BMI changes and valvulopathy in the placebo and lorcaserin groups (online-only Data Supplement Statistical Considerations). Hence, the treatment groups were combined to create a final model for the relationship between weight change and presence of FDA-defined valvulopathy ( Table III in the online-only Data Supplement). Changes from baseline in BMI and percent change in body weight were negatively associated with the presence of FDA-defined valvulopathy at week 52 (P=0.041 and P=0.026, respectively). Based on this model, 5% weight loss would be associated with an estimated odds ratio for FDAdefined valvulopathy of 1.15, and for every 2 kg/m 2 decrease in BMI, the risk is predicted to increase 1.16×. Decreases in weight and BMI were 3.3 kg and 1.2 kg/m 2 greater, respectively, in lorcaserin-treated than in placebo-treated patients, and these differential changes could at least partially explain the small difference in presence of valvulopathy in the 2 groups.
According to an analysis of the Framingham Offspring study echocardiographic data, 20 valvulopathy associated with weight loss is primarily a result of MR, because AR was not significantly associated with BMI in that study. Consistent with this prediction, the proportion of patients with FDAdefined valvulopathy as a result of MR increased from baseline to week 52 (Table 2 ). In the lorcaserin group, which experienced greater weight loss than placebo, 48.4% of valvulopathy was attributed to MR at week 52 (randomized-echo) compared with 20.4% at baseline. In the placebo group, the proportions were 25.0% at baseline and 28.8% at week 52.
Changes in Other Echocardiographic Parameters
Baseline values and changes from baseline in other echocardiographic parameters are summarized in Tables IV and V in the online-only Data Supplement, respectively. Change from baseline in the lorcaserin group differed statistically from placebo only for mitral E/A ratio; the mean changes of 0.03 and −0.01 in the lorcaserin and placebo groups, respectively, were very small and probably not clinically meaningful.
Discussion
Developing pharmacotherapy for weight reduction that is effective and also safe has proven challenging. For example, sibutramine was recently withdrawn from United States and European markets because of its tendency to increase heart rate and blood pressure and concerns about increased risk of cardiovascular events. [23] [24] [25] In the late 1990s, fenfluramine and dexfenfluramine were withdrawn when an association with valvular heart disease was recognized. 2, 4, 26 Lorcaserin was designed to stimulate the 5-HT 2C receptor without activating the 5-HT 2B receptor at therapeutic doses, thereby minimizing the risk of valvular heart disease. 7, 9, 11 The phase 3 safety and efficacy studies of lorcaserin included a comprehensive echocardiographic monitoring program that evaluated the potential risk of valvular heart disease, and the integrated analysis of those echocardiograms, described in this report, rules out a ≥1.25% risk difference in valvular regurgitation after 1 year in the lorcaserin group versus the placebo group.
Valvular insufficiency has been associated with several drugs, including the dopaminergic agonists pergolide and cabergoline and the weight loss agents fenfluramine and dexfenfluramine. Few prospective controlled studies of fenfluramine and its derivatives are available, and the risk of valvular heart disease has been primarily estimated from prevalence data. 26, 27 In a meta-analysis of studies that evaluated fenfluramine or dexfenfluramine use for >90 days (range, 211-375 days), Sachdev et al 26 reported a 12% prevalence of FDA-defined valvulopathy, compared with 6% for the unexposed control group; this translates to a prevalence odds ratio of 2.2 or a risk difference of 100% of the control prevalence. In a later meta-analysis, Hopkins et al 27 examined AR and MR associations with fenfluramine or dexfenfluramine. They reported an overall risk ratio for mild or greater AR of 19.6 (95% CI, 16.3-23.5) in people exposed to fenfluramines compared with an unexposed matched cohort. MR of moderate or greater severity was significantly associated with treatment duration, with an overall risk ratio of 5.9 (95% CI, 4.0-8.6). Prevalence data suggest that an increase in AR and MR could be detected in patients after 3 to 6 months of continuous exposure to fenfluramines. [26] [27] [28] [29] Dopamine agonists with 5-HT 2B receptor agonist activity have also been associated with valvulopathy (pergolide, cabergoline). 30 Given these historical associations between 5-HT 2B agonists and valvular heart disease, it is important to critically evaluate a potential relationship between new 5-HT receptor agonists and valvulopathy.
The present prospective analysis of >3000 patients who took lorcaserin for ≤1 year evaluated the risk of valvular regurgitation relative to a concurrent placebo-treated control population. In contrast to and as a direct result of the experience with fenfluramines, the theoretical potential for valvulopathy was appreciated a priori. As a result, the search for potential valvulopathy was enhanced by acquiring high-quality, standardized echocardiograms before any study drug was administered and then following the participants in this study during treatment. Furthermore, lorcaserin was evaluated for ≤2 years, and fenfluramine-related valve regurgitation was detected as early as 3 months. These methodological differences improved our ability to detect potential valvulopathy. The 1-year rate of echocardiographic FDA-defined valvulopathy was 2.04% in the placebo group and 2.37% in the lorcaserin group when missing values were imputed or 2.45% and 2.57%, respectively, among the patients who completed 1 year. From a clinical perspective, the differences between the placebo and lorcaserin groups are small, especially when compared with historical differences seen for fenfluramine, pergolide, or cabergoline. When the results are expressed as a risk ratio, the point estimate was 1.16 (95% CI, 0.81-1.67) in the randomized-echo population and 1.03 (95% CI, 0.68-1.57) in the completer population, ruling out risk ratios >1.67 and 1.57, respectively. In each case, the 95% CIs for the risk ratio included the value 1, indicating that the lorcaserin and placebo groups were similar.
The overall rates of FDA-defined valvulopathy were similar in the placebo and lorcaserin groups; however, the relative contributions of AR and MR to the finding of FDA-defined valvulopathy differed in the 2 groups. At the start of the study, ≈23% of patients meeting FDA-defined valvulopathy criteria did so because of MR. In the placebo group, this number increased to 27% of new cases at week 24 and 29% of new cases at week 52. In the lorcaserin group, 39% of new cases at week 24 and 48% at week 52 were attributable to MR. The analysis of valvular regurgitation is confounded by the significantly greater weight loss among the lorcaserin group. Indeed, excess adiposity seems to disproportionately impact the ability of echocardiography to detect MR. The Framingham Offspring Study performed echocardiograms on a subgroup of participants, 18 and many obese subjects were excluded from the final analysis because of technically poor echocardiograms. Nevertheless, Singh et al 18 identified a negative correlation between BMI and the prevalence of mild or greater MR or TR. The authors hypothesized that this finding could be because of the technical challenges associated with obtaining good quality images for individuals with greater adiposity or to obesity-related hemodynamic and structural changes.
Based on the conclusions from the Framingham study, we hypothesized that differential weight loss in the placebo and lorcaserin groups in the present study impacted the presence of echocardiographic valvulopathy as a result of the ability to increase the detection of MR as subjects lost weight. Applying this reasoning to the lorcaserin trials, statistical modeling predicted that a decrease in BMI would increase the apparent risk of FDA-defined valvulopathy, independent of treatment, and due predominantly to MR detection. The observation that a greater proportion of FDA-defined valvulopathy cases in the lorcaserin group were attributable to MR relative to placebo supports the hypothesis. Furthermore, the actual decrease in BMI among the lorcaserin-treated patients was 1.2 kg/m 2 greater than in the placebo group, predicting a small increase in the presence of apparent valvulopathy of ≈1.1×, consistent with the observed data. Determining whether the effect of weight loss is technical (ie, lower adiposity enables better detection of MR) or physiological will require additional investigation. However, the authors are unaware of a plausible physiological mechanism whereby a decrease in weight would increase valvular regurgitation: to the contrary, the greater decrease in systemic blood pressure observed with lorcaserin would, if anything, be expected to decrease left-sided valvular regurgitation at any given level of valvular dysfunction. In view of this and the known association of increasing adiposity and difficulty in obtaining high-quality echocardiographic imaging, it is likely that the association between weight loss and valvulopathy in our study is because of better visualization of the cardiac valves, representing only an apparent and not a physiological change.
Decreases and increases in valvular regurgitation occurred in each of the 4 heart valves among both treatment groups. The majority of shifts for the aortic, mitral, and tricuspid valves were changes of 1 grade; most changes in the aortic and mitral valves were changes from absent to trace or vice versa. Increases of 2 grades in AR or MR were infrequent and occurred with similar frequencies in both treatment groups. Furthermore, most changes were transient, with more than half of new FDA-defined valvulopathy cases at week 24 reverting to nonvalvulopathy status at week 52 in both treatment groups. Of note, in the subgroup of patients with echocardiographic FDAdefined valvulopathy at baseline, persistence of valvulopathy at both week 24 and week 52 was observed for only 57% in the placebo and 50% in the lorcaserin group. Taken together, these observations suggest that the majority of observed changes in AR and MR in these trials reflect physiological or technical variability rather than pathological changes.
In summary, the 5-HT 2C receptor agonist lorcaserin was associated with significantly greater decreases in body weight and BMI than placebo over 52 weeks in 3 large clinical trials. The presence of echocardiographic FDA-defined valvulopathy was similar in the placebo and lorcaserin treatment groups, and a slight numerical excess in the lorcaserin group translated to risk ratio estimates ranging from 1.03 to 1.16. Because decreases in BMI and body weight were negatively associated with presence of FDA-defined valvulopathy, the small difference may reflect the greater weight loss observed in the lorcaserin group compared with placebo.
